Compare DBVT & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBVT | ZVRA |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | France | United States |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.2M | 664.7M |
| IPO Year | 2014 | 2015 |
| Metric | DBVT | ZVRA |
|---|---|---|
| Price | $9.02 | $8.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $36.51 | $23.00 |
| AVG Volume (30 Days) | 300.2K | ★ 997.2K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.26 | ★ 159.21 |
| EPS | N/A | ★ 1.03 |
| Revenue | $5,636,000.00 | ★ $106,470,000.00 |
| Revenue This Year | N/A | $43.81 |
| Revenue Next Year | $1,837.59 | $15.30 |
| P/E Ratio | ★ N/A | $8.83 |
| Revenue Growth | 35.77 | ★ 350.91 |
| 52 Week Low | $8.63 | $8.01 |
| 52 Week High | $26.19 | $15.04 |
| Indicator | DBVT | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 35.83 |
| Support Level | $8.78 | N/A |
| Resistance Level | $12.41 | $9.24 |
| Average True Range (ATR) | 0.76 | 0.66 |
| MACD | -0.12 | -0.22 |
| Stochastic Oscillator | 0.97 | 0.86 |
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.